Human CD37 Protein
Catalog No: CD37-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
Product overview
Recombinant Human CD37 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the N-terminus. It contains amino acid residues Ala113-Asn240 (UniProt accession: P11049-1).
Product Details
- Molecular Aliases
- Tetraspanin-26; Tspan-26; CD37; CD37 molecule; GP52-40; MGC120234;Tspan26
- Protein Length
- Ala113-Asn240
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human CD37 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD37 is greater than 95% as determined by SEC-HPLC.
Background
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.
References
- Bobrowicz M, Kubacz M, Slusarczyk A, Winiarska M. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies. Int J Mol Sci. 2020 Dec 15;21(24):9531. doi: 10.3390/ijms21249531. PMID: 33333768; PMCID: PMC7765243. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.